Hemodynamic Management in Burn Patients with Vasopressor-Dependent Sepsis: A Preliminary Exploratory Retrospective Cohort Study
European Burn Journal · 2026-11-06 · 7 (4) · 55
DOI: 10.3390/ebj7040055 ↗Abstract
Background: Sepsis remains a leading cause of late mortality in critically ill burn patients. The optimal hemodynamic strategy, including vasopressor combinations, corticosteroids, and landiolol therapy, remains incompletely defined in this population. Objective: To examine factors associated with landiolol therapy, vasopressor strategies, and corticosteroid use in burn patients with vasopressor-dependent sepsis, and to evaluate their relationship with organ dysfunction and clinical outcomes. Methods: We conducted a preliminary exploratory retrospective cohort study in a specialized burn intensive care unit (ICU) over a three-year period (2022–2024). All mechanically ventilated adult burn patients who developed sepsis requiring vasopressor support during ICU stay were included. The primary exposure of interest was landiolol therapy; five outcomes were assessed for this exposure (ventilator-free days at day 28 after sepsis onset, duration of mechanical ventilation after sepsis onset, ICU length of stay after sepsis onset, acute kidney injury [AKI] after sepsis, and ICU mortality). Hydrocortisone administration and dual vasopressor therapy with norepinephrine plus vasopressin were evaluated as secondary descriptive exposures. Results: Thirty-one patients were included (mean age 55.8 ± 15.3 years; mean TBSA 40.2 ± 13.3%). ICU mortality was 35.5% (11/31). Landiolol was administered in 41.9% of patients; all treated patients were in sinus tachycardia (heart rate 111–140 beats/min), whereas all untreated patients had heart rates 0.99), ICU length of stay after sepsis onset (41 [21–62] vs. 56 [15–106.25] days; multiplicity-adjusted p > 0.99), AKI (2/13 vs. 5/18; OR 0.47, 95% CI 0.08–2.93; multiplicity-adjusted p > 0.99), and ICU mortality (6/13 vs. 5/18; OR 2.23, 95% CI 0.50–10.00; multiplicity-adjusted p > 0.99). The shorter total mechanical ventilation duration in landiolol-treated patients (24 [7–38] vs. 53 [18.75–79.75] days) reflected shorter ventilation before sepsis onset (6 [3–16] vs. 16.5 [10–36.75] days) and the competing risk of early death (six of eleven deaths occurred within 28 days of sepsis onset). Dual vasopressor therapy (25.8%) and hydrocortisone (19.4%) identified phenotypes of greater shock severity. Conclusions: In this small preliminary retrospective cohort, protocolized landiolol therapy in sinus-tachycardic patients was feasible and achieved heart-rate targets, but was not associated with detectable differences in clinical outcomes. These exploratory findings warrant adequately powered prospective studies in this population.
EUVIMED